Immunotherapy for lung cancer! Heat's new T cell activating cell therapy hs-110 combined with opdivo shows strong curative effect!

November 25, 2019 news / BIOON / -- heat biology is a biopharmaceutical company dedicated to the development of immunotherapy, aiming to use CD8 + "killer" T cells to activate patients' immune system against cancer Recently, the company announced the top line data of phase II clinical trial queue a (cohort a) of t-cell-activated cell therapy hs-110 combined with Bristol Myers Squibb tumor immunotherapy opdivo (odivo, common name: nivolumab, nevumab) for advanced non-small cell lung cancer (NSCLC) at the special conference of tumor immunology and immunotherapy of American Association for cancer research (AACR) Hs-110 is heat's first biological candidate in a range of patented immunotherapies designed to stimulate patients' own T cells to attack cancer Hs-110 is an allogeneic cell immunotherapy, which contains a wide range of tumor antigens known to exist in a high proportion of NSCLC patients The cell system contains gp96 immunoglobulin, which aims to make the cells express secreted gp96 Gp96 secreted as a chaperone induces cellular immune response to tumor antigens expressed by hs-110 Gp96 is a unique chaperone, which can activate MHC, up regulate T cell co stimulation, and deliver chaperoned antigen to APC The final result is to produce CD8 + T cell-mediated immune response Cohort a only included patients who had previously received treatment but never received checkpoint inhibitor (CPI), and the results published at the meeting were as follows: The results released at the meeting showed that the median overall survival time (MOS) was 16.9 months (50% of the patients were still alive at the median follow-up of 17 months), which was favorable compared with the 12.2-month data of opdivo monotherapy reported in the checkmate-057 study conducted in similar patient groups In addition, MOS was 42.1 months (95% CI: 15.8-42.1) in patients undergoing skin injection site response (ISR), and 5.9 months (95% CI: 1.4-11.6) in patients with ISR negative PFS and MOS in ISR positive group were significantly improved compared with those in ISR negative group (PFS: HR = 0.51, P = 0.042; MOS: HR = 0.14, P < 0.0001) The prospective analysis of PD-L1 negative and PD-L1 positive showed that: MOS was 16.9 months (95% CI: 5.5-unk) and 42.1 months (95% CI: 1.6-42.1), respectively The objective response rate (ORR), disease control rate (DCR) and tumor reduction rate were 22%, 48% and 46% respectively according to the criteria of immune efficacy evaluation of solid tumor (irecast) During the period of combined treatment, the T cell subsets in peripheral blood of patients with stable or improved condition decreased significantly compared with the baseline level, and the data was statistically significant Dr Jeff Hutchins, chief science and operations officer of heat, said: "the data from queue a is very encouraging and is based on our recently published data from queue B, where patients previously used checkpoint inhibitors and received hs-110 + opdivo combination therapy again Of particular interest in cohort a was a prospective definition subset of PD-L1 positive patients with a median overall survival time (MOS) of 42.1 months (95% CI: 15.8-42.1) This is particularly striking compared to the overall survival rates in the published literature on single drug therapy with first-line or second-line checkpoint inhibitors " At present, heat company has completed the phase II clinical trial of hs-110 combined with Bristol Myers Squibb tumor immunotherapy opdivo (odivo, general name: nivolumab, nevumab) or keytruda (coreda, general name: pembrolizumab, pabolizumab) in the treatment of advanced non-small cell lung cancer (NSCLC) Pelican therapeutics, a subsidiary of Pelican therapeutics, focuses on the development of costimulatory monoclonal antibodies and fusion protein therapy aimed at activating the immune system Heat also has several preclinical projects at different stages of development Source: head biology announcements additional positive top line phase 2 data of hs-110 plus nivolumab in advanced NSCLC patients